Pfizer and Acura Pharmaceuticals have announced the US FDA's approval of Oxecta, an abuse-resistant tablet formulation of the opioid oxycodone.

Excerpt

Pfizer and Acura Pharmaceuticals have announced the US FDA's approval of Oxecta, an abuse-resistant tablet formulation of the opioid oxycodone. In a press release, the manufacturers say that opioid medications are an important treatment option for moderate to severe pain; however, abuse and misuse of opioids is a serious public health issue. While OxyContin, a controlled-release formulation of oxycodone, was approved in April 2010,* Oxecta is the first immediate-release formulation of oxycodone to feature abuse-deterrent technology. Its unique composition of pharmaceutical ingredients discourages common methods of tampering, such as crushing, or mixing to form a solution. …